SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Hikal informs about submission of unaudited financial results

04 Feb 2025 Evaluate
Hikal has informed that, the Board of Directors of the Company at its meeting held today i.e., February 4, 2025, have considered and approved the unaudited financial results (Standalone and Consolidated) of the Company for the quarter and the period ended December 31, 2024. In terms of Regulation 33 of SEBI (LODR) Regulations, 2015, the unaudited financial results (Standalone and Consolidated) for the quarter and the period ended December 31, 2024 along with the Limited Review report from the Statutory Auditors are enclosed; Declared an Interim Dividend on the Equity Shares of the Company for the financial year 2024-25 @ 30% [Re 0.60 per equity share, nominal value of Rs 2 each]. The Company has fixed Record Date as Saturday, February 08, 2025, to ascertain the shareholders of the Company entitled for the payment of Interim Dividend. The Interim Dividend will be paid to the shareholder on or before Wednesday, March 5, 2025. The trading window, for trading in securities of the Company by Designated Persons, which remained closed with effect from January 1, 2025, will re-open on February 7, 2025. The special closure of trading window intimated by the Company vide its letter dated May 31, 2023 read with the outcome of Board Meeting dated November 12, 2024, will continue to remain closed for Directors, KMPs and specified senior management personnel until informed otherwise. The Meeting commenced at 11.45 am and concluded at 02.30 pm. 

The above information is a part of company’s filings submitted to BSE.

Hikal Share Price

192.15 3.60 (1.91%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×